866-997-4948(US-Canada Toll Free)

Brain Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 129 Pages


Global Markets Directs, \'Brain Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. 

Brain Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • A snapshot of the global therapeutic scenario for Brain Cancer.
  • A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy


  • Identify and understand important and diverse types of therapeutics under development for Brain Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Brain Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Brain Cancer 8
Brain Cancer Therapeutics under Development by Companies 10
Brain Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Brain Cancer Therapeutics - Products under Development by Companies 19
Brain Cancer Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Brain Cancer Therapeutics Development 22
Sanofi-Aventis 22
GlaxoSmithKline plc 23
YM BioSciences Inc. 24
Dong-A Pharmaceutical Co., Ltd. 25
Eisai Co., Ltd. 26
Nippon Shinyaku Co., Ltd. 27
Alfacell Corporation 28
Advaxis, Inc. 29
Neuralstem, Inc. 30
Bionomics Limited 31
Critical Outcome Technologies Inc. 32
Prana Biotechnology Limited 33
e-Therapeutics plc 34
AngioChem Inc. 35
Hawthorn Pharmaceuticals, Inc. 36
Pervasis Therapeutics, Inc. 37
Stemline Therapeutics, Inc. 38
Kinex Pharmaceuticals, LLC 39
Lee\'s Pharmaceutical Holdings Limited 40
TAU Therapeutics, LLC 41
Brain Cancer - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 49
Gliadel Wafer - Drug Profile 49
bafetinib - Drug Profile 50
ABT-751 - Drug Profile 52
iniparib - Drug Profile 54
COTI-2 - Drug Profile 56
AC-03-636 - Drug Profile 57
SL-302 - Drug Profile 58
SL-301 - Drug Profile 59
DA-3607 - Drug Profile 60
2,5-dimethyl celecoxib - Drug Profile 61
ADXS-HER2 - Drug Profile 62
BNC-105 - Drug Profile 63
ETS-2101 - Drug Profile 64
chlorotoxin + iron oxide nano particles - Drug Profile 66
ANG-1007 - Drug Profile 68
DC/AAT + DC/AAT-Flu + DC/KLH - Drug Profile 69
vismodegib - Drug Profile 70
vismodegib - Drug Profile 71
EGEN-001 - Drug Profile 72
ANG-1009 - Drug Profile 74
nimotuzumab + Radiation Therapy - Drug Profile 75
dabrafenib - Drug Profile 76
RMP-7 + [carboplatin] - Drug Profile 78
MK-2206 + [paclitaxel] - Drug Profile 79
PVS-30200 - Drug Profile 80
CFAKC-4 - Drug Profile 81
NSI-566RSC - Drug Profile 83
KX-02 - Drug Profile 85
VLI-01B - Drug Profile 86
PBT-519 - Drug Profile 88
BT-2111 - Drug Profile 89
procarbazine hydrochloride - Drug Profile 90
pritumumab - Drug Profile 91
DNX-2401 - Drug Profile 93
TTL-1177 + [temozolomide] - Drug Profile 95
ARN-7016 - Drug Profile 96
disulfiram - Drug Profile 97
Cancer Vaccine + CpG + Lysate - Drug Profile 98
Granulin Related Molecules - Drug Profile 99
GDOX-Related Molecules - Drug Profile 100
Brain Cancer Therapeutics - Drug Profile Updates 101
Brain Cancer Therapeutics - Discontinued Products 116
Brain Cancer Therapeutics - Dormant Products 117
Brain Cancer - Product Development Milestones 119
Featured News & Press Releases 119

Appendix 125
Methodology 125
Coverage 125
Secondary Research 125
Primary Research 125
Expert Panel Validation 125
Contact Us 126
Disclaimer 126

List of Table


Number of Products Under Development for Brain Cancer, H1 2013 11
Products under Development for Brain Cancer - Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Development by Companies, H1 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2013 17
Comparative Analysis by Late Stage Development, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2013 24
Sanofi-Aventis, H1 2013 25
GlaxoSmithKline plc, H1 2013 26
YM BioSciences Inc., H1 2013 27
Dong-A Pharmaceutical Co., Ltd., H1 2013 28
Eisai Co., Ltd., H1 2013 29
Nippon Shinyaku Co., Ltd., H1 2013 30
Alfacell Corporation, H1 2013 31
Advaxis, Inc., H1 2013 32
Neuralstem, Inc., H1 2013 33
Bionomics Limited, H1 2013 34
Critical Outcome Technologies Inc., H1 2013 35
Prana Biotechnology Limited, H1 2013 36
e-Therapeutics plc, H1 2013 37
AngioChem Inc., H1 2013 38
Hawthorn Pharmaceuticals, Inc., H1 2013 39
Pervasis Therapeutics, Inc., H1 2013 40
Stemline Therapeutics, Inc., H1 2013 41
Kinex Pharmaceuticals, LLC, H1 2013 42
Lee\'s Pharmaceutical Holdings Limited, H1 2013 43
TAU Therapeutics, LLC, H1 2013 44
Assessment by Monotherapy Products, H1 2013 45
Assessment by Combination Products, H1 2013 46
Assessment by Stage and Route of Administration, H1 2013 48
Assessment by Stage and Molecule Type, H1 2013 51
Brain Cancer Therapeutics - Drug Profile Updates 104
Brain Cancer Therapeutics - Discontinued Products 119
Brain Cancer Therapeutics - Dormant Products 120
Brain Cancer Therapeutics - Dormant Products (Contd..1) 121

List of Chart


Number of Products under Development for Brain Cancer, H1 2013 11
Products under Development for Brain Cancer - Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 16
Late Stage Products, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Discovery and Pre-Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 45
Assessment by Combination Products, H1 2013 46
Assessment by Route of Administration, H1 2013 47
Assessment by Stage and Route of Administration, H1 2013 48
Assessment by Molecule Type, H1 2013 49
Assessment by Stage and Molecule Type, H1 2013 50

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *